Ticagrelor approved for long-term treatment following MI

The antiplatelet treatment Brilique (ticagrelor) can now be prescribed in adults with a history of MI at least one year previously who are at high risk of a further atherothrombotic event.

Ticagrelor is already licensed for the initial prevention of atherothrombotic events following acute coronary syndromes. | iSTOCK
Ticagrelor is already licensed for the initial prevention of atherothrombotic events following acute coronary syndromes. | iSTOCK

The recommended dose of Brilique for patients with a history of MI is 60mg twice daily. A maintenance aspirin dose of 75—150mg should also be taken daily, unless contraindicated.

Reduction in cardiovascular events

Further information
View Brilique drug record
Summary of Product Characteristics
Manufacturer: AstraZeneca 
MIMS Cardiology Clinic

The randomised, double-blind PEGASUS TIMI-54 trial enrolled patients with a history of MI (1 to 3 years prior to randomisation) and at least one additional risk factor for atherothrombosis (n=21,162).

Ticagrelor 60mg twice daily plus low-dose aspirin significantly reduced the primary endpoint of cardiovascular death, MI or stroke at 3 years compared with placebo plus low-dose aspirin (7.77% versus 9.04%; hazard ratio 0.84, 95% CI 0.740.95, p=0.004).

Bleeding risk

Rates of major bleeding were higher with ticagrelor 60mg twice daily plus aspirin than with placebo plus aspirin (2.30% vs 1.06%, p<0.001).

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more